- Home
- CNMD vs BEAM Comparison
CNMD vs BEAM Comparison
Compare CNMD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- BEAM
- Stock Information
- Founded
- CNMD 1970
- BEAM 2017
- Country
- CNMD United States
- BEAM United States
- Employees
- CNMD N/A
- BEAM N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNMD Health Care
- BEAM Health Care
- Exchange
- CNMD Nasdaq
- BEAM Nasdaq
- Market Cap
- CNMD 1.7B
- BEAM 1.7B
- IPO Year
- CNMD 1987
- BEAM 2020
- Fundamental
- Price
- CNMD $51.32
- BEAM $24.06
- Analyst Decision
- CNMD Hold
- BEAM Strong Buy
- Analyst Count
- CNMD 5
- BEAM 10
- Target Price
- CNMD $59.80
- BEAM $49.78
- AVG Volume (30 Days)
- CNMD 318.6K
- BEAM 2.9M
- Earning Date
- CNMD 10-29-2025
- BEAM 11-04-2025
- Dividend Yield
- CNMD 1.59%
- BEAM N/A
- EPS Growth
- CNMD 12.82
- BEAM N/A
- EPS
- CNMD 3.54
- BEAM N/A
- Revenue
- CNMD $1,326,244,000.00
- BEAM $60,272,000.00
- Revenue This Year
- CNMD $6.73
- BEAM N/A
- Revenue Next Year
- CNMD $5.45
- BEAM $18.20
- P/E Ratio
- CNMD $14.19
- BEAM N/A
- Revenue Growth
- CNMD 3.94
- BEAM N/A
- 52 Week Low
- CNMD $46.00
- BEAM $13.53
- 52 Week High
- CNMD $78.00
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- CNMD 43.70
- BEAM 70.25
- Support Level
- CNMD $50.21
- BEAM $19.57
- Resistance Level
- CNMD $53.58
- BEAM $21.59
- Average True Range (ATR)
- CNMD 1.63
- BEAM 1.51
- MACD
- CNMD -0.41
- BEAM 0.58
- Stochastic Oscillator
- CNMD 16.10
- BEAM 97.10
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.